中国实用眼科杂志
中國實用眼科雜誌
중국실용안과잡지
CHINESE JOURNAL OF PRACTICAL OPHTHALMOLOGY
2014年
10期
1220-1222
,共3页
单志明%陈秀英%郭硕%陈国%王海青%任凤杰%王伟
單誌明%陳秀英%郭碩%陳國%王海青%任鳳傑%王偉
단지명%진수영%곽석%진국%왕해청%임봉걸%왕위
玻璃体积血%视网膜静脉分支闭塞%荧光素血管造影术
玻璃體積血%視網膜靜脈分支閉塞%熒光素血管造影術
파리체적혈%시망막정맥분지폐새%형광소혈관조영술
Vitreous hemorrhage%Branch retinal vein occlusion%Fundus fluorescein angiography
目的 探讨首发症状为玻璃体积血视网膜分支静脉阻塞(BRVO)的荧光素眼底血管造影(FFA)诊断及临床特点.方法 回顾性分析2009年1月至2011年12月在秦皇岛市第一医院眼科以玻璃体积血为首发症状而就诊的97例97只眼BRVO病例的FFA特点及临床资料.结果 97只眼玻璃体积血分别为:Ⅰ级玻璃体积血38只眼,占39.18% (38/97).Ⅱ、Ⅲ级玻璃体积血59只眼,占60.82% (59/97).发现视网膜血管白鞘67只眼,占69.07% (67/97).全部病例经FFA检查明确诊断为BRVO,FFA显示阻塞区毛细血管大片闭塞,阻塞区边缘毛细血管瘤样扩张.其中81只眼,占83.51% (81/97),发现大小、数量不等的视网膜新生血管.颞上BRVO 66只眼,占68.04% (66/97).颞下BRVO 13只眼,占13.40% (13/97).鼻上BRVO 11只眼,占11.34% (11/97).鼻下BRVO 7只眼,占7.22%(7/97).阻塞静脉分支级别为:一级分支18只眼,均为鼻侧静脉分支,占18.56% (18/97).二、三级分支79只眼,均为颞侧静脉的周边分支,占81.44%(79/97).伴增殖膜13只眼,占13.40% (13/97).继发视网膜浅脱离10只眼,占10.31% (10/97).结论 首发症状为玻璃体积血的BRVO病例,静脉分支均为鼻侧静脉分支及颞侧静脉分支中的周边分支.发生玻璃体积血前均无症状.玻璃体积血多为Ⅰ级-Ⅲ级.FFA可明确诊断.发病人群为伴有高血压病的中老年.
目的 探討首髮癥狀為玻璃體積血視網膜分支靜脈阻塞(BRVO)的熒光素眼底血管造影(FFA)診斷及臨床特點.方法 迴顧性分析2009年1月至2011年12月在秦皇島市第一醫院眼科以玻璃體積血為首髮癥狀而就診的97例97隻眼BRVO病例的FFA特點及臨床資料.結果 97隻眼玻璃體積血分彆為:Ⅰ級玻璃體積血38隻眼,佔39.18% (38/97).Ⅱ、Ⅲ級玻璃體積血59隻眼,佔60.82% (59/97).髮現視網膜血管白鞘67隻眼,佔69.07% (67/97).全部病例經FFA檢查明確診斷為BRVO,FFA顯示阻塞區毛細血管大片閉塞,阻塞區邊緣毛細血管瘤樣擴張.其中81隻眼,佔83.51% (81/97),髮現大小、數量不等的視網膜新生血管.顳上BRVO 66隻眼,佔68.04% (66/97).顳下BRVO 13隻眼,佔13.40% (13/97).鼻上BRVO 11隻眼,佔11.34% (11/97).鼻下BRVO 7隻眼,佔7.22%(7/97).阻塞靜脈分支級彆為:一級分支18隻眼,均為鼻側靜脈分支,佔18.56% (18/97).二、三級分支79隻眼,均為顳側靜脈的週邊分支,佔81.44%(79/97).伴增殖膜13隻眼,佔13.40% (13/97).繼髮視網膜淺脫離10隻眼,佔10.31% (10/97).結論 首髮癥狀為玻璃體積血的BRVO病例,靜脈分支均為鼻側靜脈分支及顳側靜脈分支中的週邊分支.髮生玻璃體積血前均無癥狀.玻璃體積血多為Ⅰ級-Ⅲ級.FFA可明確診斷.髮病人群為伴有高血壓病的中老年.
목적 탐토수발증상위파리체적혈시망막분지정맥조새(BRVO)적형광소안저혈관조영(FFA)진단급림상특점.방법 회고성분석2009년1월지2011년12월재진황도시제일의원안과이파리체적혈위수발증상이취진적97례97지안BRVO병례적FFA특점급림상자료.결과 97지안파리체적혈분별위:Ⅰ급파리체적혈38지안,점39.18% (38/97).Ⅱ、Ⅲ급파리체적혈59지안,점60.82% (59/97).발현시망막혈관백초67지안,점69.07% (67/97).전부병례경FFA검사명학진단위BRVO,FFA현시조새구모세혈관대편폐새,조새구변연모세혈관류양확장.기중81지안,점83.51% (81/97),발현대소、수량불등적시망막신생혈관.섭상BRVO 66지안,점68.04% (66/97).섭하BRVO 13지안,점13.40% (13/97).비상BRVO 11지안,점11.34% (11/97).비하BRVO 7지안,점7.22%(7/97).조새정맥분지급별위:일급분지18지안,균위비측정맥분지,점18.56% (18/97).이、삼급분지79지안,균위섭측정맥적주변분지,점81.44%(79/97).반증식막13지안,점13.40% (13/97).계발시망막천탈리10지안,점10.31% (10/97).결론 수발증상위파리체적혈적BRVO병례,정맥분지균위비측정맥분지급섭측정맥분지중적주변분지.발생파리체적혈전균무증상.파리체적혈다위Ⅰ급-Ⅲ급.FFA가명학진단.발병인군위반유고혈압병적중노년.
Objective To investigate the diagnosis and clinical characteristics of vitreous hemorrhage in branch retinal vein occlusion(BRVO)fundus fluorescein angiography(FFA)as the first symptoms.Methods A retrospective analysis of the FFA characteristics and clinical data of 97 cases(97 eyes)with BRVO cases which had vitreous hemorrhage as the first symptom treatment.Results Of 97 eyes of vitreous hemorrhage,respectively:Class I vitreous hemorrhage 38,accounted for 39.18%,Class Ⅱ,Ⅲ vitreous hemorrhage 59,accounted for 60.82%.Retinal vascular white sheath 67,accounted for 69.07%.All patients were BRVO with clear diagnosis by FFA.FFA showed that there was occlusion area capillary large block,block area edge to expand capillary tumor samples in all cases.The size and number of retinal neovascularization were found in 81 eyes(83.51%),BRVO 66 eyes on the temporal,accounted for 68.04%; Under the temporal BRVO 13 eyes 13 eyes,accounted for 13.40%; On the nose of BRVO 11 eyes,accounted for 11.34%; Under the nose of BRVO 7 eyes,accounted for 7.22%.Blocking venous branch level:Primary branches were 18 eyes,which were a branch the nasal vein branches,accounted for 18.56%.Secondary and tertiary branches were of 79 eyes,which were peripheral branch of the temporal side of the vein,accounted for 81.44%.With proliferation of membrane 13 eyes,accounted for 13.40%; retinal detachment 10,accounted for 10.31%.Conclusions BRVO cases of vitreous hemorrhage as the first symptom are the peripheral branch of the nasal vein branch retinal vein branch and the temporal side of the vein branches and are asymptomatic before the vitreous hemorrhage,vitreous hemorrhage for grade Ⅰ-Ⅲ level.FFA can confirm the diagnosis.The crowd of the disease has occurred among middle-aged and old hypertension.